377769-51-2

Basic information

• Product Name: 5-(N-(4-butylphenyl)sulfaMoyl)-2-Methylbenzoic acid
• Synonyms: 5-(N-(4-butylphenyl)sulfaMoyl)-2-Methylbenzoic acid;5-[[(4-butylphenyl)amino]sulfonyl]-2-methylBenzoic acid;OTSNMUDJXINAKM-UHFFFAOYSA-N
• CAS NO: 377769-51-2
• Molecular Formula: C₁₈H₂₁NO₄S
• Molecular Weight: 347.42864
• Mol File: 377769-51-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(N-(4-butylphenyl)sulfaMoyl)-2-Methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(N-(4-butylphenyl)sulfaMoyl)-2-Methylbenzoic acid(377769-51-2)
• EPA Substance Registry System: 5-(N-(4-butylphenyl)sulfaMoyl)-2-Methylbenzoic acid(377769-51-2)

Safety Data

• Hazardous Substances Data: 377769-51-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-(N-(4-butylphenyl)sulfamoyl)-2-methylbenzoic acid is used as a potential active pharmaceutical ingredient for the development of new drugs, leveraging its sulfonamide functional group's known antibacterial and diuretic properties.
Used in Antibacterial Applications:
In the field of infectious diseases, 5-(N-(4-butylphenyl)sulfamoyl)-2-methylbenzoic acid is used as an antibacterial agent, targeting a range of bacterial infections by inhibiting essential bacterial processes, thereby contributing to treatment and prevention strategies.
Used in Diuretic Formulations:
5-(N-(4-butylphenyl)sulfamoyl)-2-methylbenzoic acid is utilized as a diuretic in the treatment of conditions that require increased urine output, such as hypertension and edema, by promoting the excretion of excess water and salts from the body.

Upstream product

• 89001-57-0 5-(chlorosulfonyl)-2-methylbenzenecarboxylic acid 
• 13478-63-2 p-butylaniline hydrochloride 
• 118-90-1 ortho-methylbenzoic acid 
• 104-13-2 4-Butylaniline 

Downstream Products

• 1245034-88-1 N-(4-butylphenyl)-4-methyl-3-(4-phenylpiperazine-1-carbonyl)benzenesulfonamide 
• 721888-90-0 N-(4-butylphenyl)-3-(4-(2-methoxyphenyl)piperazine-1-carbonyl)-4-methylbenzenesulfonamide 
• 1245034-92-7 N-(4-butylphenyl)-4-methyl-3-(4-(pyridin-2-yl)piperazine-1-carbonyl)benzenesulfonamide 
• 1311382-59-8 N-(4-butylphenyl)-3-(4-(2-isopropylphenyl)piperazine-1-carbonyl)-4-methylbenzenesulfonamide 
• 1311383-70-6 tert-butyl 4-(5-(N-(4-butylphenyl)sulfamoyl)-2-methylbenzoyl)piperazine-1-carboxylate 
• 1311383-71-7 N-(4-butylphenyl)-4-methyl-3-(piperazine-1-carbonyl)benzenesulfonamide 
• 1311383-16-0 N-(4-butylphenyl)-4-methyl-3-(4-(2-methylbenzyl)piperazine-1-carbonyl)benzenesulfonamide 
• 1311383-28-4 C₂₇H₃₈N₄O₄S 
• 1311383-29-5 ethyl 4-(5-(N-(4-butylphenyl)sulfamoyl)-2-methylbenzoyl)piperazine-1-carboxylate 
• 1311382-76-9 3-(4-(2-bromophenyl)piperazine-1-carbonyl)-N-(4-butylphenyl)-4-methylbenzenesulfonamide 

Relevant articles and documents

The landscape of the anti-kinase activity of the IDH1 inhibitors

Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among oth

THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION

Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. The compounds and compositions can be used to modulate an isocitrate dehydrogenase (IDH) mutant (e.g., IDHIm or IDH2m) having alpha hydroxyl neoactivity